Full-Time

Global Brand Associate Director COPD

Posted on 4/16/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

Compensation Overview

$180.9k - $271.3k/yr

+ Short-term incentive bonus + Equity-based long-term incentive program + Commission payment eligibility

Senior, Expert

Gaithersburg, MD, USA + 1 more

More locations: Wilmington, DE, USA

The job requires a minimum of three days per week in the office, indicating a hybrid work model.

Category
Brand & Creative Marketing
Growth & Marketing
Required Skills
Market Research
Branding/Brand Strategy
Marketing
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a AstraZeneca referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Bachelor’s degree is required with business degree or scientific expertise as preferred
  • A minimum of 5 to 10 years’ marketing experience in healthcare or biopharma industry, with a strong preference for experience in the respiratory therapeutic area
  • Demonstrated experience of leading a marketing campaign implementation in global or significant global market
  • In-depth understanding of commercial strategy, methodologies, and tools (product profiling and positioning, forecasting, pricing & reimbursement, market research techniques, competitive intelligence resources)
  • Generating sales forecasts and business cases
  • Experience of shaping brand strategy whilst the understanding of product profile was incomplete and evolving
  • Proven experience of engaging with and leveraging insights from external customers e.g. KEEs, prescribers, payors
Responsibilities
  • Leading the development and implementation of the brand pre launch and promotional activity plan
  • Coordinating the roll out of global initiatives / projects and engagement plans (for example brand forums and congresses) with focus on the G8-12 markets
  • Being an active member of the global commercial working group and extended GBT
  • Engaging with the local marketing teams to ensure a flawless and aligned execution of the promotional plan
  • Provide promotional input to the global strategy / BSP
  • Engaging with KEEs to gather input to inform the promotional strategy and activities plan including advocacy development
Desired Qualifications
  • Strong understanding and experience of launching medicines in the US health system

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before they reach the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by providing effective treatments for serious diseases while collaborating with the scientific community to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • Enhertu shows promise in early-stage breast cancer treatment.
  • AI-powered tools enhance lung cancer detection capabilities.
  • Calquence combination approved in EU for chronic lymphocytic leukaemia.

What critics are saying

  • Discontinuation of Truqap trial impacts oncology pipeline.
  • High capital investment in Rockville cell therapy site poses financial risks.
  • AI tools introduce data privacy and algorithmic bias concerns.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapy areas.
  • The company invests heavily in R&D for innovative drug development.
  • AstraZeneca's A.Catalyst Network fosters global health innovation collaborations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
May 9th, 2025
Imfinzi Improved Dfs In Early Bladder Cancer

Imfinzi improved DFS in early bladder cancer

Cision
May 7th, 2025
Enhertu Improved Pcr In Early-Stage Breast Cancer

Enhertu improved pCR in early-stage breast cancer

PharmiWeb
May 7th, 2025
Enhertu Followed By Thp Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In Patients With High-Risk Her2-Positive Early-Stage Breast Cancer In Destiny-Breast11 Phase Iii Trial

AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer. Positive high-level results from the DESTINY-Breast11 Phase III trial showed Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment. The secondary endpoint of event-free survival (EFS) was not mature at the time of analysis; however, EFS data showed an early positive trend favouring Enhertu followed by THP compared to standard of care. The trial will continue to follow EFS

Bethesda Magazine
May 6th, 2025
AstraZeneca opens cell therapy manufacturing site in Rockville

AstraZeneca announced in February 2024 that it was investing in the Rockville manufacturing facility.

Cision
May 6th, 2025
Calquence Combination Approved In Eu For 1L Mcl

Calquence combination approved in EU for 1L MCL

INACTIVE